.Pharmacolibrary.Drugs.ATC.B.B01AC04 .Pharmacolibrary.Drugs.ATC.B.B01AC04| name: | Clopidogrel |
| ATC code: | B01AC04 | route: | oral |
| n-compartments | 1 |
Clopidogrel is an oral antiplatelet agent that inhibits ADP-induced platelet aggregation by antagonizing the P2Y12 receptor. It is used to prevent atherothrombotic events in patients with myocardial infarction, stroke, or established peripheral arterial disease. Clopidogrel is currently approved and widely used in clinical practice.
Pharmacokinetic parameters reported for healthy adult male and female volunteers receiving a single 75 mg oral dose of clopidogrel.
Mahar, KM, et al., & Goulooze, SC (2024). Integrated Population Pharmacokinetics of Daprodustat in Patients with Chronic Kidney Disease with Anemia. Clinical pharmacokinetics 63(9) 1327–1341. DOI:10.1007/s40262-024-01417-9 PUBMED:https://pubmed.ncbi.nlm.nih.gov/39259485
Zhang, L, et al., & Yan, X (2022). Semi-mechanistic population pharmacokinetics analysis reveals distinct CYP2C19 dependency in the bioactivation of vicagrel and clopidogrel to active metabolite M15-2. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 177 106264–None. DOI:10.1016/j.ejps.2022.106264 PUBMED:https://pubmed.ncbi.nlm.nih.gov/35868434
Rekić, D, et al., & Hamrén, B (2021). Pharmacokinetics of Roxadustat: A Population Analysis of 2855 Dialysis- and Non-Dialysis-Dependent Patients with Chronic Kidney Disease. Clinical pharmacokinetics 60(6) 759–773. DOI:10.1007/s40262-020-00974-z PUBMED:https://pubmed.ncbi.nlm.nih.gov/33486718